



COLLABORATIVE WORKING EXECUTIVE SUMMARY

Project Title: Test and Treat Influenza Pathway Optimisation Pilot Project

Project Description

Roche Products Limited, Roche Diagnostics Limited and the Innovation Agency North West Coast Academic Health Science Network (AHSN) are working together under a Collaborative Working Agreement to support the design and implementation of a community influenza patient pathway that incorporates a rapid antigen test, enabling prompt diagnosis and appropriate treatment for patients.

Organisations Involved

Roche Products Limited, Roche Diagnostics Limited & The Innovation Agency North West Coast AHSN, including pilot sites across the North of England:

- Healthier South Wirral Primary Care Network,
- Oaklands Health Centre, Huddersfield and Slaithwaite Health Centre, Holmfirth
- Priory Medical Group - York
- Cumbria Health On Call
- Cruddas Park and Hills View Surgeries, Newcastle
- Abbey Court and Kenton Hall Care/Nursing Homes, Newcastle
- Lanercost House and Rosehill: Care/Nursing Homes, Cumbria
- The Millfield Care/Nursing Home, Keswick

Other organisations involved in this project are:

- Yorkshire and Humber AHSN (in collaboration with the Innovation Agency) - to support and liaise with sites in their area and promote the project locally
- North East North Cumbria AHSN (in collaboration with the Innovation Agency) - to support and liaise with sites in their area and promote the project locally
- Unity Insights – providing independent real world evaluation and case evidence generation
- Healthcall - a NHS owned Company, providing App development and digital connectivity across all sites

Project Rationale

All parties involved in this collaborative working project are dedicated to supporting the NHS to improve the current influenza patient pathway. This pilot project will deliver the design and implementation of a service to test for flu in the community, enabling prompt diagnosis and appropriate treatment of at-risk patients.

The main aims of this project include improving outcomes for patients, reducing hospital admissions and identifying the service impact through real world evaluation.

All parties are working in partnership under a collaborative working agreement to:

- Identify barriers to the current influenza pathway and create an optimal community pathway which looks to improve patient outcomes and reduce hospitalisations in a community setting
- Design and implement a flu test and treat pilot during the 22/23 influenza season
- Collect data to generate evidence to support the commissioning of a new influenza pathway nationally
- Empower patients, clinicians and the general public to recognise influenza as a major contributor to winter pressure in the health and care system and mortality

Project period

Pilot Start Date: Nov 22

Pilot End Date: June 23

Intended Project Outcome

Benefit for patients

Earlier diagnosis and appropriate treatment of influenza would benefit high-risk patients, potentially reducing the risk of complications including hospitalisation enabling overall improvement in care. In addition, we hope to generate evidence to show that this concept could lead to public health benefits with decreased community transmission, protecting vulnerable, high-risk patients including those in care and residential homes.

Benefit to the NHS

Testing and treating patients in the community could reduce the number of unnecessary referrals to secondary care, prevent hospitalisations and avoidable patient deaths. In addition, an optimal patient pathway may improve appropriate healthcare utilisation & prescribing where appropriate. It could also help to improve healthcare resource utilisation at a critical time in the recovery from the COVID-19 pandemic.

Benefit to Roche

Roche will benefit from partnering with the AHSN to understand and improve the influenza patient pathway. In addition, it will benefit from collating a wide variety of data on the influenza patient pathway from various settings including Primary Care Networks, Care and Nursing Homes. It could also benefit from potential use of Roche diagnostic tests and medicines in the community.

This document has been produced by Roche Products Ltd, Roche Diagnostics Ltd & The Innovation Agency North West Coast AHSN